EZZ Life Science Holdings Ltd - Asset Resilience Ratio
EZZ Life Science Holdings Ltd (EZZ) has an Asset Resilience Ratio of 2.63% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read EZZ Life Science Holdings Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how EZZ Life Science Holdings Ltd's Asset Resilience Ratio has changed over time. See EZZ Life Science Holdings Ltd (EZZ) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down EZZ Life Science Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EZZ Life Science Holdings Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$891.50K | 2.63% |
| Total Liquid Assets | AU$891.50K | 2.63% |
Asset Resilience Insights
- Limited Liquidity: EZZ Life Science Holdings Ltd maintains only 2.63% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
EZZ Life Science Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare EZZ Life Science Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for EZZ Life Science Holdings Ltd (2023–2024)
The table below shows the annual Asset Resilience Ratio data for EZZ Life Science Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.63% | AU$891.50K ≈ $630.79K |
AU$33.96 Million ≈ $24.03 Million |
+0.45pp |
| 2023-12-31 | 2.18% | AU$556.49K ≈ $393.75K |
AU$25.55 Million ≈ $18.08 Million |
-- |
About EZZ Life Science Holdings Ltd
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia. The company operates through two segments, Brought in Lines and Company Owned Products. It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consum… Read more